Irinotecan for children with relapsed solid tumors.
Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
Shitara
Toshiji
T
Department of Hematology/Oncology, Gunma Children's Medical Center, Seta-gun, Gunma, Japan. shitara@gcmc.pref.gunma.jp
Shimada
Akira
A
Hanada
Ryoji
R
Matsunaga
Tadashi
T
Kawa
Keisei
K
Mugishima
Hideo
H
Sugimoto
Tohru
T
Mimaya
Jun-ichi
J
Manabe
Atsushi
A
Tsurusawa
Masahito
M
Tsuchida
Yoshiaki
Y
D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D000077146:Irinotecan; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D012008:Recurrence; D012074:Remission Induction; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D047368:Tumor Burden / Q000187:drug effects; D009396:Wilms Tumor / Q000188:drug therapy
D000077146:Irinotecan; D002166:Camptothecin